Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Longest survival follow-up ever reported for immunotherapy treatment in this setting
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Sun Pharma's Dadra facility receives OAI status from US FDA
A significant proportion of healthcare professionals still tend to favor branded drugs
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Subscribe To Our Newsletter & Stay Updated
